Recombinant Cynomolgus Glypican 3 / GPC3 Protein, Llama IgG2b Fc Tag, low endotoxin, 100 µg

Background
Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.

Source
Recombinant Cynomolgus Glypican 3, Llama IgG2b Fc Tag, low endotoxin (GP3-C5259) is expressed from human 293 cells (HEK293). It contains AA Gln 25 - His 559 (Accession # XP_005594665.1).
Predicted N-terminus: Gln 25 & Ser 359

Molecular Characterization
This protein carries a llama IgG2b Fc tag at the C-terminus. This protein contains a furin-like convertase cleavage site, 355-RQYR-358, and will be partially processed into N and C-terminal fragment with calculated MW of 38.1 kDa and 50.5 kDa respectively. The protein migrates as 40 kDa, 60 kDa and 100-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.01 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances"
Li, Lin, Hong et al
Adv Cancer Res (2022) 156, 415-449
(2)  "Frequently Expressed Glypican-3 As A Promising Novel Therapeutic Target for Osteosarcomas"
Nie, Yang, Li et al
Cancer Sci (2022)
(3) "Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma"
Muralidharan, Kervarrec, Weiss et al
Oncotarget (2022) 13, 960-967
Showing 1-3 of 1770 papers.